Mayo Clinic medical experts in hypertrophic cardiomyopathy, Jeffrey B. Geske, M.D., Steve R. Ommen, M.D., and Hartzell V. Schaff, M.D., discuss the recent publication of the "2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy."
They review the top changes to the guideline, including the introduction of a cardiac myosin
inhibitor, mavacamten, for support of people with symptomatic obstructive hypertrophic cardiomyopathy (HCM); the evolved guidelines for healthy levels of exercise; the formal split in sudden cardiac death risk assessment between children and adults living with HCM; and new advice on more frequent screening for individuals who have risk factors for atrial fibrillation.
Learn more, [ Ссылка ]
From Mayo Clinic to your inbox, sign-up for free: [ Ссылка ]
Visit Mayo Clinic: [ Ссылка ]
Like Mayo Clinic on Facebook: [ Ссылка ]
Follow Mayo Clinic on Instagram: [ Ссылка ]
Follow Mayo Clinic on X, formerly Twitter: [ Ссылка ]
Follow Mayo Clinic on Threads: [ Ссылка ]
